Nature Communications (Sep 2021)
Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
- Fabin Dang,
- Li Nie,
- Jin Zhou,
- Kouhei Shimizu,
- Chen Chu,
- Zhong Wu,
- Anne Fassl,
- Shizhong Ke,
- Yuangao Wang,
- Jinfang Zhang,
- Tao Zhang,
- Zhenbo Tu,
- Hiroyuki Inuzuka,
- Piotr Sicinski,
- Adam J. Bass,
- Wenyi Wei
Affiliations
- Fabin Dang
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School
- Li Nie
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School
- Jin Zhou
- Department of Liver Surgery & Liver Transplantation, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Kouhei Shimizu
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School
- Chen Chu
- Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School
- Zhong Wu
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Anne Fassl
- Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School
- Shizhong Ke
- Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- Yuangao Wang
- Program in Cellular and Molecular Medicine, Boston Children’s Hospital
- Jinfang Zhang
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School
- Tao Zhang
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School
- Zhenbo Tu
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School
- Hiroyuki Inuzuka
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School
- Piotr Sicinski
- Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School
- Adam J. Bass
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Wenyi Wei
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-021-25700-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 15
Abstract
Acquisition of CDK4/6i resistance represents a major clinical challenge. Here, the authors report that inhibition of CK1ε can prevent acquisition of CDK4/6i resistance, potentiating the therapeutic efficacy of CDK4/6i in human breast cancer.
